SCHEMBL8229391

SCHEMBL8229391

c1ccc(C2C[N+]23CCCCC3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.34
HDAC4 P56524 1/20 0.33
TSHR P16473 1/20 0.33
SLC18A3 Q16572 1/20 0.32
MAOA P21397 6/20 0.32
MAOB P27338 6/20 0.32
KDM1A O60341 4/20 0.32
CYP2C19 P33261 4/20 0.32
CYP2B6 P20813 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
CYP2A6 P11509 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2C P28335 1/20 0.32
ADRA1A P35348 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13532274 1.00 RECQL (0.34) RECQLHDAC4TSHRSLC18A3MAOA
SCHEMBL9370820 0.67 CHRM2 (0.47)
SCHEMBL8497209 0.65 ALDH1A1 (0.36) RECQLHDAC4SLC18A3LMNA
SCHEMBL16226181 0.65 TSHR (0.37) TSHRSLC18A3MAOAMAOBKDM1A
SCHEMBL7054926 0.63 ALOX15 (0.37) SLC18A3
SCHEMBL447032 0.59 SLC18A3 (0.63) TSHRSLC18A3CYP2C19CYP1A2CYP2D6
SCHEMBL19198566 0.59 SLC18A3 (0.63) TSHRSLC18A3CYP2C19CYP1A2CYP2D6
SCHEMBL1616696 0.59 PABPC1 (0.38) CYP2B6CYP1A2CYP2C9LMNASLC6A2
SCHEMBL790829 0.59 SLC18A3 (0.63) TSHRSLC18A3CYP2C19CYP1A2CYP2D6
SCHEMBL42833 0.59 SLC18A3 (0.63) TSHRSLC18A3CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541593-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-24 US disclosed
US-8541593-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-24 US disclosed
US-8536345-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-17 US disclosed
US-8536345-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-17 US disclosed
US-20110160463-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES AMGEN INC. 2011-06-30 US disclosed
US-20100280255-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES AMGEN INC. (US) 2010-11-04 US disclosed
WO-2007113309-A2 COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF GLAXO GROUP LIMITED (GB) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280255-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES HSD11B1, HSD11B2, HSD17B1 RECQL 427/4885HDAC4 1016/4885TSHR 1338/4885
US-20110160463-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES HSD11B1, HSD11B2, HSD17B1 RECQL 489/4885HDAC4 957/4885TSHR 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.